{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022505","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.106700+00:00","generated_at":"2026-05-16T19:56:28.586792+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mangoceuticals clarifies GLP-1 programs: no direct contracts with Eli Lilly or Novo Nordisk","bullets":["MangoRx Direct and PeachesRx Direct can prescribe branded GLP-1s (Zepbound, Wegovy) via third-party provider.","Company has no direct contractual relationship with Eli Lilly or Novo Nordisk; access is through an independent provider.","Programs launched Nov 13, 2025 at $99/month; medication cost and fulfillment separate.","Clarification follows earlier press release that may have implied direct partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022505","json":"https://secwatch.observer/filing/0001493152-25-022505.json","markdown":"https://secwatch.observer/filing/0001493152-25-022505.md","text":"https://secwatch.observer/filing/0001493152-25-022505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/0001493152-25-022505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:56:28.586792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}